Evaluation of tumor mutation burden (TMB) in tumor (tDNA) and plasma cell free DNA (cfDNA) in patients (pts) with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with a combination of cetuximab and nivolumab (C+N).
Year: 2023
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Christine H. Chung, Graydon Moorhead, Nicholas Haradhvala, Laxmi Parida, Jiannong Li, Robbert Slebos, Xiaofei Song, Ritu Chaudhary, Maria Poole, Robin Park, Kedar Kirtane, Conor Ernst Steuer, Nabil F. Saba, Priyanka Bhateja, James William Rocco, Marcelo Raul Bonomi, Brian Danysh, Gad Getz, Aik-choon Tan
Institutions: Moffitt Cancer Center, Broad Institute, IBM (United States), Emory University, Winship Cancer Institute, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Huntsman Cancer Institute
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4379337444